Table 1.
Demographic data.
| Characteristic | CL (n = 50) Mean (SD) | PD (n = 47) Mean (SD) | p |
|---|---|---|---|
| Male/female (n) | m 27, f 23 | m 34, f 13 | 0.062 |
| Age (years) | 69.8 (7.2) | 69.1 (8.3) | 0.694 |
| MMSE (0 - 30) | 28.4 (1.7) | 28.3 (2.0) | 0.827 |
| MoCA (0 - 30)+ | 27.6 (2.4) | 26.0 (3.8) | 0.016 |
| GDS (0 - 15) | 1.0 (1.5) | 2.7 (2.7) | <0.001 |
| MFI Total fatigue (20 - 100) | 34.7 (13.2) | 49.9 (18.6) | <0.001 |
| ABCs (0 - 100 %) | 91.7 (11.0) | 80.4 (18.4) | 0.001 |
| Hoehn & Yahr stage (n) | - | HY I 5 | - |
| HY II 39 | |||
| HY III 3 | |||
| Levodopa Equivalent Daily Dose | - | 419.6 (214.0) | - |
| MDS-UPDRS III | - | 32.0 (10.1) | - |
| Freezing of gait (n, %) | - | 7 (14.9 %) | - |
| Motor Phenotype (n) | - | PIGD 18 | - |
| ID 6 | |||
| TD 23 |
MMSE mini mental state exam, MoCA montreal cognitive assessment, GDS geriatric depression scale, MFI multidimensional fatigue inventory, ABCs activities specific balance confidence scale, UPDRS Unified Parkinson’s disease rating scale, PIGD postural instability and gait disorder phenotype, ID indeterminate phenotype, TD tremor dominant phenotype. p difference between CL and people with PD. In bold significant p values (p < 0.05)
Clinical and demographic characteristics for control participants (CL), and people with Parkinson’s disease (PD). In bold are shown significant p values < 0.05